Hubei Jumpcan Pharmaceutical (600566.SH): cooperative product Maseki Lopinavir tablets obtain Drug Registration Certificate.

20/07/2025

Jichuan Pharmaceutical Industry (600566.SH) announced that its wholly-owned subsidiary Jichuan Pharmaceutical Group Co., Ltd. (...

Hubei Jumpcan Pharmaceutical (600566.SH) announced that recently, its wholly-owned subsidiary Hubei Jumpcan Pharmaceutical Group Co., Ltd. (referred to as "Jichuan Limited") has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the development of Marzulse Lowasarvir Tablets in cooperation with Nanjing Zhengxiang Pharmaceutical Co., Ltd. (referred to as "Zhengxiang Pharmaceutical"). Marzulse Lowasarvir Tablet is a class 1 new drug applied by Zhengxiang Pharmaceutical. It is a new generation of polymerase acidic protein (PA) nucleoprotein inhibitor with broad-spectrum anti-influenza virus characteristics. The approved indications for this drug are for the treatment of previously healthy adult patients with simple type A and B influenza, excluding patients at high risk of influenza-related complications.

Kaisa Capital (00936): Yu Huiming has been appointed as an executive director.

HAO TIAN INTL (01341) plans to issue a discount of approximately 12.28% for the placement of up to 1.524 billion shares, raising approximately HK$300 million.

IVD MEDICAL(01931): Application for stablecoin license in the United States and the official launch of the IVDNewCo Exchange ecosystem.

Kaisa Capital (00936): Yu Huiming has been appointed as an executive director.

HAO TIAN INTL (01341) plans to issue a discount of approximately 12.28% for the placement of up to 1.524 billion shares, raising approximately HK$300 million.

IVD MEDICAL(01931): Application for stablecoin license in the United States and the official launch of the IVDNewCo Exchange ecosystem.